Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli
Margaret F. Bennewitz, … , Mark T. Gladwin, Prithu Sundd
Margaret F. Bennewitz, … , Mark T. Gladwin, Prithu Sundd
Published January 12, 2017
Citation Information: JCI Insight. 2017;2(1):e89761. https://doi.org/10.1172/jci.insight.89761.
View: Text | PDF
Research Article Hematology Inflammation

Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli

  • Text
  • PDF
Abstract

In patients with sickle cell disease (SCD), the polymerization of intraerythrocytic hemoglobin S promotes downstream vaso-occlusive events in the microvasculature. While vaso-occlusion is known to occur in the lung, often in the context of systemic vaso-occlusive crisis and the acute chest syndrome, the pathophysiological mechanisms that incite lung injury are unknown. We used intravital microscopy of the lung in transgenic humanized SCD mice to monitor acute vaso-occlusive events following an acute dose of systemic lipopolysaccharide sufficient to trigger events in SCD but not control mice. We observed cellular microembolism of precapillary pulmonary arteriolar bottlenecks by neutrophil-platelet aggregates. Blood from SCD patients was next studied under flow in an in vitro microfluidic system. Similar to the pulmonary circulation, circulating platelets nucleated around arrested neutrophils, translating to a greater number and duration of neutrophil-platelet interactions compared with normal human blood. Inhibition of platelet P-selectin with function-blocking antibody attenuated the neutrophil-platelet interactions in SCD patient blood in vitro and resolved pulmonary arteriole microembolism in SCD mice in vivo. These results establish the relevance of neutrophil-platelet aggregate formation in lung arterioles in promoting lung vaso-occlusion in SCD and highlight the therapeutic potential of targeting platelet adhesion molecules to prevent acute chest syndrome.

Authors

Margaret F. Bennewitz, Maritza A. Jimenez, Ravi Vats, Egemen Tutuncuoglu, Jude Jonassaint, Gregory J. Kato, Mark T. Gladwin, Prithu Sundd

×

Figure 1

0.1 μg/kg IV LPS triggers pulmonary vaso-occlusion in SCD mice.

Options: View larger image (or click on image) Download as PowerPoint
0.1 μg/kg IV LPS triggers pulmonary vaso-occlusion in SCD mice.
Control ...
Control and sickle cell disease (SCD) mice were injected intravenously (IV) with saline (n = 3 mice per group; control: 23 fields of view [FOVs]; SCD: 29 FOVs) or 0.1 μg/kg LPS (n = 5 mice per group; control: 54 FOVs; SCD: 48 FOVs). Arterioles were imaged 2–2.5 hours after IV saline or 0.1 μg/kg IV LPS using qFILM. (A and B) qFILM images showing 2 pulmonary vaso-occlusions (dotted ellipses) in SCD mice (A) and an absence of pulmonary vaso-occlusions in control mice (B) administered 0.1 μg/kg IV LPS. Supplemental Video 3 shows the FOV in A. Pulmonary arteriolar vaso-occlusions were quantified as described in Supplemental Methods. (C) Number of pulmonary vaso-occlusions (PVO) per FOV for control (black circles) and SCD mice (white circles) administered IV saline or IV LPS. Size of FOV: ~67,600 μm2. (D) Percent FOVs with pulmonary vaso-occlusions in SCD and control mice administered IV saline or IV LPS. (E) Conceptual schematic of pulmonary vaso-occlusions. Large neutrophil-platelet aggregates (yellow dotted ellipses) block arteriolar bottlenecks. Neutrophil vaso-occlusion (red arrow): few platelets (green) adhered to a neutrophil macro-aggregate (red). Platelet vaso-occlusion (green arrow): few neutrophils embedded inside a platelet macro-aggregate. Erythrocytes (purple) are trapped within neutrophil-platelet aggregates. Black arrow denotes direction of blood flow. Asterisks denote alveoli. (F) qFILM image of a SCD mouse challenged with 0.1 μg/kg IV LPS. All 4 arteriolar bottlenecks are blocked by neutrophil (red arrows) or platelet (green arrows) vaso-occlusions. (G) Neutrophil vaso-occlusion (magnified from F) showing mostly neutrophils (red) bound to few platelets (green). (H) Platelet vaso-occlusion (magnified from F) showing mostly platelets bound to one neutrophil (white arrow). Pulmonary microcirculation is shown in purple. White arrows in A, B, and F denote direction of blood flow. Diameter of arteriole shown in F is ~28 μm. Scale bars: 20 μm. Supplemental Video 7 shows the FOV in F. (I) Number of pulmonary vaso-occlusions per FOV classified by cellular composition. (J) Number of pulmonary vaso-occlusions per FOV with area <1,000 μm2 or >1,000 μm2. Average number of pulmonary vaso-occlusions per FOV, cellular composition of pulmonary vaso-occlusions, and area of pulmonary vaso-occlusions were compared using t tests with Bonferroni correction. Percent of FOVs with pulmonary vaso-occlusions were compared using 4-fold table analyses with Bonferroni χ2 statistics. Data represent mean ± SEM. *P < 0.05 for control vs. SCD and #P < 0.05 for IV saline vs. 0.1 μg/kg IV LPS.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts